Tiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injury

Tiziana Life Sciences (NASDAQ:TLSA) has been awarded a US Department of Defense (DoD) research grant to advance its intranasal anti-CD3 therapy for traumatic spinal cord injury (SCI), resulting in an almost 11% pre-market share price increase. The grant will support a three-year study on acute SCI, alongside a Stepping Strong Breakthrough Award for chronic SCI, aiming to address the significant unmet medical need for therapies that improve neurological recovery and mitigate inflammation in this patient population. This funding underscores the potential of their non-invasive, immune-modulating therapy in a field lacking approved treatments.

Analysis

Tiziana Life Sciences (NASDAQ:TLSA) has received a significant external validation for its therapeutic pipeline, securing a US Department of Defense (DoD) research grant to advance its intranasal anti-CD3 therapy for spinal cord injury (SCI). The market reacted strongly to this development, with the company's shares adding almost 11% in pre-market trading. The grant provides non-dilutive funding for a three-year study on the acute phase of SCI, while a complementary two-year Stepping Strong Breakthrough Award will support research into the chronic phase. This dual-pronged approach addresses a major unmet medical need, as the article notes nearly 300,000 Americans live with permanent disability from SCI and no approved therapies currently exist to improve neurological recovery. The therapy's potential is supported by preclinical results from Brigham and Women’s Hospital which demonstrated improved motor outcomes. According to program head Dr. Saef Izzy, the non-invasive, immune-modulating therapy could "change the trajectory of injury" by addressing the chronic inflammation that damages the spinal cord post-trauma, signaling a pivotal move from discovery to clinical translation.

Key Decisions for Investors

• The DoD grant provides significant external validation and non-dilutive funding for Tiziana's SCI program, warranting a re-evaluation of the company's development pipeline and long-term potential in a market with a high unmet need.
• Given the early-stage nature of the therapy, investors should treat TLSA as a speculative holding, with the 11% pre-market jump reflecting positive sentiment that must be followed by successful clinical data to be sustained.
• Key catalysts to monitor will be the initiation and subsequent data readouts from the three-year acute and two-year chronic SCI studies, as progress in translating preclinical results to human trials is critical for de-risking the asset and unlocking further value.